Prediction: Novo Nordisk Will Soar Over the Next 5 Years. Here's 1 Reason Why.

After quite a crushing bull stampede in 2024, the stock price of weight loss drug star Novo Nordisk (NYSE: NVO) has come down considerably. But I think that not only will the Wegovy maker recover, it'll zoom much higher in the coming years. Read on to find out why.

Widened waistlines

If you could flag only one type of medication that's perfectly targeted to the huge U.S. market, it would be weight loss drugs.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Obesity is an American problem that's not getting better; according to research published in The Lancet medical journal and cited by U.S. News and World Report, the obesity rate here more than doubled in percentage terms from 1990 to 2022. In the former year, slightly over 21% of U.S. adults were obese. Thirty-two years later, that figure was nearly 44%.

And that's just in the U.S. -- obesity affected more than 1 billion people worldwide in 2022. So it's no surprise to learn that analysts are expecting sales of weight loss drugs to balloon. In 2024, this tally exceeded $30 billion worldwide for the first time.

And that's peanuts. In May of last year, investment bank Morgan Stanley adjusted its forecast for 2030 sales from $77 billion to at least $105 billion, and perhaps as much as $144 billion. At the very least, that's a potentially more than threefold increase in the space of barely over half a decade.

Staying in the game

Novo Nordisk and Eli Lilly (with its Zepbound) are the two reigning kings on the U.S. market these days. There will be more contenders; Viking Therapeutics, in particular, is in the later stages of developing a treatment that's performed well in trials.

But especially in big jurisdictions like the U.S. and the European Union, it takes time to get a medicine approved. Meanwhile, Wegovy has become the go-to drug for obesity treatment, and incumbency has power in the pharmaceutical world. Even if Novo Nordisk loses considerable share to a giant like Eli Lilly and/or an upstart, it should still have a significant piece of a rapidly enlarging pie.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $328,354!*
• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $46,837!*
• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $527,017!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Learn more »

*Stock Advisor returns as of February 24, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.